GreenLight SPAC Presentation Deck

CBH GreenLight Covid vaccine has considerable potential Endemic Covid expected to drive global vaccine demand to ~$20B in 2027 Covid-19 Challenge Only 21 doses for every 100 people have been administered worldwide Periodic booster dose may be necessary Widespread Covid-19 vaccinations will not be achieved until 2023 Late 2021 Source: Economist Intelligence Unit, January 2021 Mid 2022 Late 2022 from early 2023 Our Proposed Solution Covid-19 variant updated vaccine candidate Proprietary RNA manufacturing platform Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. Target profile advantages compared to traditional vaccine production • Integrated, scalable, proprietary manufacturing platform less dependent on key raw materials supply Small production footprint to produce billions of doses of Covid-19 vaccines or annual boosters rapidly adapted to address new variants of concern • Cost-competitive, especially for middle- and low-income countries HUMAN HEALTH 51

View entire presentation